Norfloxacin treatment for clinically significant portal hypertension: Results of a randomised double-blind placebo-controlled crossover trial

Liver International

Volumn 29, Issue 3, 2009, Pages 427-433

  Kemp, William ^a,b   Colman, John ^b   Thompson, Kenneth ^b   Madan, Anoop ^b   Vincent, Margaret ^c   Chin Dusting, Jaye ^c   Kompa, Andrew ^a   Krum, Henry ^a   Roberts, Stuart ^b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cirrhosis; Endotoxaemia; Nitric oxide; Norfloxacin; Portal hypertension; Urotensin II

Indexed keywords

AMINO ACID TRANSPORTER; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NORFLOXACIN; PLACEBO; TUMOR NECROSIS FACTOR; UROTENSIN II;

ADULT; ALCOHOL CONSUMPTION; AMINO ACID TRANSPORT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIMULUS LYSATE TEST; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ARGININE; CROSS-OVER STUDIES; ENDOTOXEMIA; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; NORFLOXACIN; PORTAL PRESSURE; STATISTICS, NONPARAMETRIC; UROTENSINS; VICTORIA;

EID: 59849111712     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01850.x     Document Type: Article

References (44)

1. Lata J, Jurankova J, Husova L, et al. Variceal bleeding in portal hypertension: Bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics -a randomized trial. Eur J Gastroenterol Hepatol 2005; 17: 1105-10.
2. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: A meta-analysis. Hepatology 1999; 29: 1655-61.
3. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial. Hepatology 2004; 39: 746-53.
4. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27: 1207-12.
5. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999; 353: 139-42.
6. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-41.
7. Chin-Dusting JP, Rasaratnam B, Jennings GL, Dudley FJ. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 1997; 127: 985-8.
8. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139: 186-93.
9. Albillos A, de la Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
10. Rasaratnam B, Connelly N, Chin-Dusting J. Nitric oxide and the hyperdynamic circulation in cirrhosis: Is there a role for selective intestinal decontamination? Clin Sci 2004; 107: 425-34.
11. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: Relationship to endotoxemia. Hepatology 1993; 18: 1139-43.
12. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.
13. Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 2001; 5: 629-44.
14. Vo PA, Lad B, Tomlinson JA, Francis S, Ahluwalia A. Autoregulatory role of endothelium-derived nitric oxide (NO) on lipopolysaccharide-induced vascular inducible NO synthase expression and function. J Biol Chem 2005; 280: 7236-43.
15. Rasaratnam B, Chin-Dusting J, Kaye D, Ahlers BA, Jennings G, Dudley F. Arterial vasodilation in cirrhosis: Role of the l-Arginine transporter system. J Gastroenterol Hepatol 1999; 14 (Suppl. 1): A122.
16. Schwartz IF, Schwartz D, Traskonov M, et al. l-Arginine transport is augmented through up-regulation of tubular CAT-2 mRNA in ischemic acute renal failure in rats. Kidney Int 2002; 62: 1700-6.
17. Kaye DM, Ahlers BA, Autelitano DJ, Chin-Dusting JP. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 2000; 102: 2707-12.
18. Kaye DM, Parnell MM, Ahlers BA. Reduced myocardial and systemic l -arginine uptake in heart failure. Circ Res 2002; 91: 1198-203.
19. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39: 280-2.
20. Abdelrahman AM, Pang CC. Involvement of the nitric oxide/l-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 2002; 71: 819-25.
21. Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996; 25: 370-8.
22. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103: 235-9.
23. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104: 1750-4.
24. Garcia-Pagan JC, Bosch J, Rodes J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis 1995; 6: 140-7.
25. Kapoor D, Sarin SK. Pathophysiology of portal hypertension. J Gastroenterol Hepatol 2002; 17 (Suppl.): S482-7.
26. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-7.
27. Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103: 1267-72.
28. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Levy VG. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996; 24: 802-6.
29. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: 481-8.
30. Aracil C, Lopez-Balaguer JM, Monfort D, et al. Hemodynamic response to beta-blockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis. Hepatology 2003; 38 (Suppl. 4): 296A.
31. Closs EI, Scheld JS, Sharafi M, Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: Role of cationic amino acid transporters. Mol Pharmacol 2000; 57: 68-74.
32. Rockey DC, Shah V. Nitric oxide biology and the liver: Report of an AASLD research workshop. Hepatology 2004; 39: 250-7.
33. McDonald KK, Zharikov S, Block ER, Kilberg MS. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J Biol Chem 1997; 272: 31213-6.
34. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002; 37: 767-72.
35. Kemp W, Krum H, Colman J, et al. Urotensin II: A novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 2007; 27: 1232-9.
36. Trebicka J, Hennenberg M, Eckhardt A, Biecker E, Sauerbruch T, Heller J. Urotensin II receptor antagonist Palosuran lowers portal pressure and improves renal perfusion in cirrhotic rats. Hepatology 2006; 44 (Suppl. 1): 202A.
37. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401: 282-6.
38. Douglas SA, Sulpizio AC, Piercy V, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000; 131: 1262-74.
39. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000; 130: 1865-70.
40. Lacza Z, D WB. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 2006; 78: 2763-6.
41. Zhang AY, Chen YF, Zhang DX, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003; 285: F792-8.
42. Lin L, Ding WH, Jiang W, et al. Urotensin-II activates l-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 2004; 25: 1977-84.
43. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324: 384-94.
44. UpToDate. Norfloxacin: Drug information. Lexi-Comp Inc., 2007.